Effect of combined local treatment with zoledronic acid and basic fibroblast growth factor on implant fixation in ovariectomized rats

Effect of combined local treatment with zoledronic acid and basic fibroblast growth factor on implant fixation in ovariectomized rats
复制标题

DOI:
10.1016/j.bone.2008.10.054
复制
发表时间:
2009-02-01
期刊:
影响因子:
4.1
通讯作者:
Li, Jihua
Li, Jihua
中科院分区:
医学2区
文献类型:
--
作者:
Gao, Ying;Luo, En;Li, Jihua

文献摘要

被引文献

相似文献

骨质疏松症是一种骨骼疾病,其特征在于低骨量和骨微结构的恶化,导致骨脆性,这损害了植入物的固定。唑来膦酸(ZOL)是破骨细胞介导的骨吸收的潜在抑制剂,碱性成纤维细胞生长因子(bFGF)是刺激成骨细胞介导的骨形成的生长因子,这些药物可以在骨质疏松条件下增强植入物的固定。本研究将40只去卵巢大鼠随机分为4组(每组n=10),并使用羟基磷灰石(HA)涂层钛植入物进行双侧钛植入:对照组(植入前蒸馏水浸泡),ZOL组bFGF组(20 μ g/ml bFGF浸泡); ZOL+bFGF组(1 mg/ml ZOL +20 μ g/ml bFGF浸泡)。术后3个月处死动物,取胫骨进行组织学、显微CT和生物力学测试。通过组织形态计量学分析确定的骨面积和接触,与对照组相比,ZOL处理的种植体为2.7倍和1.8倍,bFGF处理的种植体为1.9倍和1.8倍,两种处理的种植体为3.6倍和2.3倍(p
osteoporosis is a skeletal disorder characterized by low bone mass and deterioration of bone microarchitecture resulting in bone fragility, which impairs fixation of the implants. Zoledronic acid (ZOL) is a potential inhibitor of osteoclast-mediated bone resorption and basic fibroblast growth factor (bFGF) is a growth factor that stimulates osteoblast-mediated bone formation, and these drugs could enhance fixation of implants under osteoporotic conditions. In this Study, 40 ovariectomized (OVX) rats were randomly divided into 4 groups (n=10 for each group) and underwent bilateral tibiae implantation using hydroxyapatite (HA)-coated titanium implant: Control group (distilled water immersing before implantation), ZOL group (1 mg/ml of ZOL immersing), bFGF group (20 mu g/ml of bFGF immersing), and ZOL+bFGF group (1 mg/ml of ZOL and 20 mu g/ml of bFGF immersing). At 3 months after implantation, all animal were sacrificed and the tibiae were harvested for histology, micro-CT examinations and biomechanical testing. Bone area and contact, determined by histomorphometric analysis, were 2.7-fold and 1.8-fold in the ZOL-treated implants, 1.9-fold and 1.8-fold in the bFGF-treated implants, 3.6-fold and 2.3-fold in the both-treated implants compared with controls (p